Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 9/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.37 |
| ▸ | ITGAV | P06756 | 5/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375043 | 0.89 | POLB (0.45) | ELANEPOLB | |
| SCHEMBL820456 | 0.89 | POLB (0.45) | ELANEPOLB | |
| SCHEMBL820670 | 0.88 | ELANE (0.36) | ELANEITGB1ITGA5ITGB3ITGAV | |
| SCHEMBL818205 | 0.82 | MET (0.41) | HCRTR1HCRTR2ITGB1ITGA5ITGB3 | |
| SCHEMBL820249 | 0.82 | MET (0.41) | HCRTR1HCRTR2ITGB1ITGA5ITGB3 | |
| SCHEMBL820565 | 0.78 | ERAP2 (0.43) | — | |
| SCHEMBL818648 | 0.73 | TSHR (0.45) | — | |
| SCHEMBL820466 | 0.73 | TSHR (0.45) | — | |
| SCHEMBL946384 | 0.72 | TGM2 (0.41) | POLB | |
| SCHEMBL12944880 | 0.72 | TGM2 (0.41) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2409984-A1 | Dimeric IAP Antagonists | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | ELANE 2407/4885HCRTR1 4665/4885HCRTR2 4581/4885 |
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | ELANE 616/4885HCRTR1 4617/4885HCRTR2 4775/4885 |
| US-20110305777-A1 | DIMERIC IAP ANTAGONISTS | BIRC2, BIRC7, BIRC8 | ELANE 2140/4885HCRTR1 4299/4885HCRTR2 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.